Neumora Revenue and Competitors

Boston, MA USA

Location

#2821

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Neumora's estimated annual revenue is currently $24.8M per year.(i)
  • Neumora's estimated revenue per employee is $155,000

Employee Data

  • Neumora has 160 Employees.(i)
  • Neumora grew their employee count by 7% last year.

Neumora's People

NameTitleEmail/Phone
1
Co-founder, Executive ChairmanReveal Email/Phone
2
VP Clinical OperationsReveal Email/Phone
3
VP, Program LeadershipReveal Email/Phone
4
VP, Head Translational ScienceReveal Email/Phone
5
VP, Head Corporate DevelopmentReveal Email/Phone
6
VP Asset LeadershipReveal Email/Phone
7
VP, Discovery ChemistryReveal Email/Phone
8
VP, Head IPReveal Email/Phone
9
VP, Associate General CounselReveal Email/Phone
10
SVP, Business Technology & Digital HealthReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Neumora?

Brain diseases are not “one-size-fits-all” - but the industry currently treats them that way. At Neumora, our mission is to transform the treatment and patient outcomes for brain diseases – with precision. Our proprietary toolbox of state-of-the-art neural network technologies is built to integrate multiple types of data across genomics, imaging, electroencephalogram (EEG), digital and clinical domains to create Data Biopsy Signatures™ that map the underlying disease mechanisms to Precision Phenotypes™ that identify distinct patient subtypes. Through this approach, we have the ability to develop and match the right therapeutic to the right patient populations for more targeted treatments. Together, we are committed to creating a new era in modern precision medicine. Brain disease doesn’t wait. And neither will we.

keywords:N/A

N/A

Total Funding

160

Number of Employees

$24.8M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Neumora News

2022-04-13 - Biotech venture capital: Top 10 money-raisers of 2021

Neumora's second clinical-phase program is a V1aR antagonist that is in phase 1 development as a treatment for anxiety disorders. Having emerged...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.8M1607%N/A
#2
$17.9M1635%N/A
#3
$33.3M1687%N/A
#4
$18.9M17215%N/A
#5
$26.8M17330%N/A